Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Cancer · 2024
DOI: 10.1002/cncr.35156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Francesca Palandri und 36 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Anemia, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Background
Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2 ‐inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF patients unexposed to RUX.
Methods
The authors investigated the incidence of BP in 886 RUX‐treated MF patients, included in the “RUX‐MF” retrospective study.
Results
The BP incidence rate ratio (IRR) was 3.74 per 100 patient‐years (3.74 %p‐y). At therapy start, Common Terminology Criteria for Adverse Events grade 3‐4 anemia (hemoglobin [Hb]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", Università di Catania, Catania, Italy.
- Division of Hematology, Città della Salute e della Scienza Hospital, Torino, Italy.
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- IRCCS San Gerardo dei Tintori, Divisione di Ematologia e Unità Trapianto di Midollo, Monza, Italy.
- Hematology, S.Eugenio Hospital, Tor Vergata University, Rome, Italy.
ORCID-Profile: Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, Elena M Elli, Elisabetta Abruzzese, Mario Tiribelli, Novella Pugliese, Massimiliano Bonifacio, Massimo Breccia
Förderung
- Ministero della Salute
Zitieren
APA
Palandri, F., Palumbo, G. A., Benevolo, G., Iurlo, A., Elli, E. M., Abruzzese, E., Polverelli, N., Tiribelli, M., Auteri, G., Tieghi, A., Caocci, G., Binotto, G., Cavazzini, F., Branzanti, F., Beggiato, E., Miglino, M., Bosi, C., Crugnola, M., Bocchia, M., …, & Breccia, M. (2024). Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. https://doi.org/10.1002/cncr.35156
Vancouver
Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, et al. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2024. doi:10.1002/cncr.35156
BibTeX
@article{Palandri2024,
author = {Palandri, Francesca and Palumbo, Giuseppe A and Benevolo, Giulia and Iurlo, Alessandra and Elli, Elena M and Abruzzese, Elisabetta and Polverelli, Nicola and Tiribelli, Mario and Auteri, Giuseppe and Tieghi, Alessia and Caocci, Giovanni and Binotto, Gianni and Cavazzini, Francesco and Branzanti, Filippo and Beggiato, Eloise and Miglino, Maurizio and Bosi, Costanza and Crugnola, Monica and Bocchia, Monica and Martino, Bruno and Pugliese, Novella and Scaffidi, Luigi and Venturi, Marta and Duminuco, Andrea and Isidori, Alessandro and Cattaneo, Daniele and Krampera, Mauro and Pane, Fabrizio and Cilloni, Daniela and Semenzato, Gianpietro and Lemoli, Roberto M and Cuneo, Antonio and Trawinska, Malgorzata M and Vianelli, Nicola and Cavo, Michele and Bonifacio, Massimiliano and Breccia, Massimo},
title = {Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35156}
}
EUVIMED